CGRP Receptor Antagonists in the Acute Treatment of Migraine and Preventive Treatment of Episodic Migraine
Released On
March 10, 2025
Expires On
March 10, 2026
Media Type
Internet
Completion Time
30 minutes
Specialty
Neurology
Topic(s)
Migraines
Sponsored by Pfizer
This activity is supported in part by an independent education grant from Pfizer.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credits™
- Nurses — 0.5 Nursing Contact Hours
- Physician Assistants — 0.5 AAPA Category 1 CME credits
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of all healthcare professionals (HCPs), including physicians and allied health providers, who are directly involved in patient care and manage patients on a daily basis.
Program Overview
This activity will cover the latest advances in CGRP receptor antagonists for migraine management. The presentation begins with an overview of CGRP’s role in migraine pathophysiology, followed by an in-depth exploration of how CGRP receptor antagonists work to block CGRP signaling, offering new hope in both acute and preventive migraine treatment. Experts will then discuss clinical trial data, including the efficacy and safety profiles of these treatments, as well as patient-reported outcomes. The session also addresses practical considerations for integrating CGRP receptor antagonists into clinical practice, offering insights on patient selection, side effect management, and optimizing patient response.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recognize the mechanisms of action of CGRP receptor antagonists in the acute treatment of migraine and their role in preventing episodic migraine.
- Review the latest clinical data on the safety and efficacy of CGRP receptor antagonists for migraine treatment.
- Differentiate between CGRP receptor antagonists and other available migraine treatments in terms of therapeutic outcomes and patient suitability.
- Implement evidence-based strategies to integrate CGRP receptor antagonists into clinical practice for both acute and preventive migraine management.
Faculty
Dr. Cynthia Armand
Neurologist
Associate Professor of Neurology, Albert Einstein College of Medicine
Program Director, Montefiore Headache Center
Clinical Director, Montefiore Headache Center
Bronx, NY
Dr. Larry Charleston IV
Neurologist
Founder & Chief Consultant
Charleston Health Neurology & Head Pain Consultants
Detroit, MI
Dr. Hope O’Brien
Neurologist
Founder & CEO, Headache Center of Hope
Cincinnati, OH
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
PA Continuing Medical Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until March 10, 2026. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Disclosures of Conflicts of Interest
Cynthia Armand, MD
Consulting fees: Pfizer and Tonix Pharmaceuticals.
Honoraria for non-CME: Pfizer.
Larry Charleston IV, MD, MSc, FAHS, FANA
Consulting fees: AbbVie, Accolade, Amgen, Anneal, Aurene, Haleon, LinPharma, Mi-Helper Inc., Pfizer, and Satsuma.
Grant funding: Amgen.
Stock Ownership: Mi-Helper Inc.
Hope O’Brien, MD, MBA, FAHS, FAAN
Consulting fees: : AbbVie, Lilly, Pfizer, Guidepoint, and Bausch Health.
Grant funding: AbbVie and Lilly
Speakers Bureau : AbbVie, Lilly, Pfizer, and Seilex.
Royalties: UptoDate.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for immediate download by the participant.
Course Viewing Requirements
Support Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The Postgraduate Institute for Medicine requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].